Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases

肺生物学和肺部疾病中的干细胞、细胞疗法和生物工程

基本信息

批准号：
10318408
负责人：
Amy Leanne Ryan
金额：
$ 3万
依托单位：
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-23 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10318408
关键词：
3-Dimensional Address Adult Respiratory Distress Syndrome American Animal Model Area Award Basic Science Biology Biomedical Engineering Blinded COVID-19 COVID-19 pandemic Cell Therapy Cells Chest Chronic Obstructive Airway Disease Clinic Clinical Clinical Research Clinical Trials Communication Communities Critical Illness Cystic Fibrosis Data Development Disease Equilibrium European Event Faculty Fostering Foundations Funding Funding Agency Funding Opportunities Future Goals Grant Growth Guidelines Hybrids Immune response Injury International Journals Lung Lung diseases Malignant neoplasm of lung Mentors Minority Minority Groups Molecular Motivation National Heart, Lung, and Blood Institute Natural regeneration Oral Participant Pathologic Persons Pre-Clinical Model Publishing Pulmonary Fibrosis Pulmonary Hypertension Recommendation Regulation Research Research Personnel Research Support Role Science Sepsis Series Societies Stem Cell Research Techniques Technology Therapeutic Time Tissue Engineering Training Translating Translational Research Transplantation Travel Underrepresented Minority United States National Aeronautics and Space Administration United States National Institutes of Health Universities Vermont Woman airway regeneration base career career development cell type clinical investigation combat design graduate student induced pluripotent stem cell innovation insight lung development lung injury lung regeneration meetings phrases postdoctoral investigator posters repaired respiratory scaffold skill acquisition stem cell therapy stem cells symposium translational study

项目摘要

Repair and regeneration of diseased lung with stem cells or bioengineered tissue are exciting potential therapeutic approaches for a variety of lung diseases and critical illnesses. Increasing evidence in preclinical models suggests that cells which are not normally resident in the lung can be utilized to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those utilizing stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise and differentiate during lung development and in normal and pathologic repair and remodeling after lung injury. We have held eight previous biennial conferences at the University of Vermont from 2005 through 2019. These have brought together leading international investigators with junior faculty and trainees to discuss issues in this rapidly moving field. These conferences have been highly successful and have resulted in a series of guidelines for basic, translational, and clinical research to be utilized by both investigators and funding agencies. As studies on stem cell and cell therapies for lung diseases continues to move at a rapid pace and the field explores how to best translate these approaches, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and leading non-profit respiratory disease foundations to discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials, particularly as there have now been clinical investigations of various cell types for a number of conditions including ARDS, BPD, COPD, IPF, pulmonary hypertension, sepsis, and more recently COVID-19. As with prior conferences a particular focus will be on rising junior investigators and trainees and how to further develop careers in this area. As always, junior investigators, trainees, and investigators from underrepresented minority groups will be prioritized for inclusion in conference organization, oral presentations, chairing activities, discussions, and poster sessions. Trainees will be able to compete for an increased number of travel awards based on blinded review of submitted abstracts. The conference is planned for July 2021 at the University of Vermont with plans for a switch from a hybrid conference to a fully online conference if necessary due to ongoing COVID-19 pandemic restrictions. We anticipate that this conference will continue to foster extensive discussion and debate and will significantly guide directions in basic, translational, and clinical research of stem cells, cell therapies, and bioengineering approaches for lung diseases.

用干细胞或生物工程组织修复和再生患病肺部具有令人兴奋的潜力多种肺部疾病和危重疾病的治疗方法。越来越多的临床前证据模型表明，通常不驻留在肺部的细胞可用于调节免疫损伤后的反应，但将这些有希望的发现转化为临床仍面临挑战。在与此同时，研究人造肺和无细胞肺用途的生物工程研究激增基质作为三维肺或气道再生的支架，最近的一些尝试大型动物模型移植。这些研究与利用干细胞的研究相结合，诱导多能干细胞衍生物和/或细胞疗法是一项有前途且快速发展的研究区域。这些研究进一步平行于对分子和分子的理解的显着增加。内源性肺干细胞和/或祖细胞在肺过程中产生和分化的细胞事件发育以及肺损伤后的正常和病理修复和重塑。我们已经举办了八届 2005 年至 2019 年在佛蒙特大学举办的每两年一次的会议。这些会议带来了领先的国际研究人员与初级教师和学员一起快速讨论这一领域的问题移动场。这些会议非常成功，并产生了一系列指导方针供研究人员和资助机构使用的基础、转化和临床研究。作为研究肺部疾病的干细胞和细胞疗法继续快速发展，该领域正在探索如何为了最好地转化这些方法，我们建议再次召集相关调查人员以及来自 NHLBI、FDA 和领先的非营利性呼吸系统疾病基金会的代表讨论了当前的问题。特别要讨论的一个领域是基础研究和转化研究之间的平衡以及临床试验的作用，特别是现在已经对各种细胞类型进行了临床研究多种疾病，包括 ARDS、BPD、COPD、IPF、肺动脉高压、脓毒症等新冠肺炎。与之前的会议一样，特别关注的是正在崛起的初级研究人员和实习生，以及如何进一步发展该领域的职业生涯。一如既往，初级调查员、实习生和调查员来自代表性不足的少数群体将被优先纳入会议组织、口头发言、主持活动、讨论和海报会议。受训者将能够竞争更多的人数基于对提交的摘要进行盲审的旅行奖励。会议计划于 2021 年 7 月在佛蒙特大学计划从混合会议转向完全在线会议，如果由于持续的 COVID-19 大流行限制，这是必要的。我们预计本次会议将继续促进广泛的讨论和辩论，并将显着指导基础、转化和临床方向干细胞、细胞疗法和肺部疾病生物工程方法的研究。